Article History
Received: 2 May 2023
Revised: 31 July 2023
Accepted: 1 August 2023
First Online: 21 September 2023
Declarations
:
: Joshua M. Thurman holds stock in and receives royalties from Q32 Bio, Inc., a company developing complement inhibitors. Marina Vivarelli receives consulting fees from Novartis, Roche, Bayer, Apellis, BioCryst, Travere, WebMD, PureSpring, and Chinook; participated in sponsored trials by Alexion, Roche, Novartis, Bayer, Chinook, Travere, and Apellis; and received speaker fees from Alexion, Glaxo, Roche, Novartis, and Vifor. These have no impact on the current publication. Luca Antonucci declares no conflicts of interest.